Hepatotoxicity Induced by Adalimumab in Chronic Plaque Psoriasis Patient: A Case Report.

INTRODUCTION

Adalimumab is a TNF-α antagonist used to treat psoriasis and rheumatologic conditions; it can rarely cause hepatotoxicity manifesting as elevated liver enzymes.

CASE PRESENTATION: Here, we present a case of a 24-year-old female with chronic plaque psoriasis with no history of liver disease or any risk factor for liver disease who developed a drug-induced liver injury upon treatment initiation with Adalimumab. This case report highlights the importance of monitoring liver function tests in patients receiving Adalimumab, early recognition, and prompt medication dosage adjustment or discontinuation. Early diagnosis and treatment of chronic plaque psoriasis is critical for improving prognosis, especially in the case of increased risk factors of liver disease due to the administration of Adalimumab.

CONCLUSION

Our case presented a patient with no history of liver disease; however, she developed a drug-induced liver injury. Therefore, this case report is the first to emphasize the need for early recognition of LFTs upon Adalimumab administration, and prompt medication dosage adjustment or discontinuation is essential in patients receiving Adalimumab.